Literature DB >> 11043164

The International Collaborative Study of Maternal Phenylketonuria: status report 1998.

R Koch1, E Friedman, C Azen, W Hanley, H Levy, R Matalon, B Rouse, F Trefz, S Waisbren, K Michals-Matalon, P Acosta, F Güttler, K Ullrich, L Platt, F de la Cruz.   

Abstract

UNLABELLED: The Maternal Phenylketonuria Study began in 1984 and during the intervening years, 572 pregnancies in hyperphenylalaninemic women and 99 controls and their outcomes have been evaluated. Among hyperphenylalaninemic women who delivered a live infant, only 15.9% were treated and in metabolic control preconceptually, however, another 18.4% were in control by 10 weeks. Compared to the results reported by Lenke and Levy in 1980, there is a marked improvement in outcome with treatment. Microcephaly was unusual in preconceptually treated pregnancies with well controlled phenylalanine restricted diets. Even in pregnancies that established control after conception but before the 8th week, congenital heart disease did not occur in the offspring, however, it did occur in 12% of pregnancies not achieving control until after 10 weeks of pregnancy.
CONCLUSION: The recommended level of blood phenylalanine during pregnancy is 120-360 mumol/l. Best results were obtained by close cooperation between the attending obstetrician and a metabolic team experienced in the care of persons with phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043164     DOI: 10.1007/pl00014383

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation.

Authors:  Raphaël Teissier; Emmanuel Nowak; Murielle Assoun; Karine Mention; Aline Cano; Alain Fouilhoux; François Feillet; Hélène Ogier; Emmanuel Oger; Loïc de Parscau
Journal:  J Inherit Metab Dis       Date:  2012-06-05       Impact factor: 4.982

2.  Maternal phenylketonuria: report from the United Kingdom Registry 1978-97.

Authors:  P J Lee; D Ridout; J H Walter; F Cockburn
Journal:  Arch Dis Child       Date:  2005-02       Impact factor: 3.791

3.  Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases.

Authors:  François Feillet; Ania C Muntau; François-Guillaume Debray; Amelie S Lotz-Havla; Alexandra Puchwein-Schwepcke; Ma'atem Béatrice Fofou-Caillierez; Francjan van Spronsen; Fritz Friedrich Trefz
Journal:  J Inherit Metab Dis       Date:  2014-05-01       Impact factor: 4.982

4.  Maternal hyperphenylalaninemia: rapid achievement of metabolic control predicts overall control throughout pregnancy.

Authors:  Teresa Martino; Celide Koerner; Gayane Yenokyan; Julie Hoover-Fong; Ada Hamosh
Journal:  Mol Genet Metab       Date:  2013-02-19       Impact factor: 4.797

5.  Maternal phenylketonuria: the French survey.

Authors:  François Feillet; Véronique Abadie; Jacques Berthelot; Nicole Maurin; Hélène Ogier; Michel Vidailhet; Jean-Pierre Farriaux; Loic de Parscau
Journal:  Eur J Pediatr       Date:  2004-07-06       Impact factor: 3.183

6.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

Review 7.  State-of-the-art 2003 on PKU gene therapy.

Authors:  Zhaobing Ding; Cary O Harding; Beat Thöny
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

8.  Short-term dietary interventions in children and adolescents with treated phenylketonuria: effects on neuropsychological outcome of a well-controlled population.

Authors:  S C J Huijbregts; L M J de Sonneville; R Licht; F J van Spronsen; J A Sergeant
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

Review 9.  A practical approach to maternal phenylketonuria management.

Authors:  F Maillot; P Cook; M Lilburn; P J Lee
Journal:  J Inherit Metab Dis       Date:  2007-03-09       Impact factor: 4.750

10.  Cell encapsulation as a potential nondietary therapy for maternal phenylketonuria.

Authors:  Donna A Santillan; Mark K Santillan; Stephen K Hunter
Journal:  Am J Obstet Gynecol       Date:  2009-07-24       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.